At the feed-mill transfer line discharging 25 kg paper sacks for piglet creep feed, the API is first de-lumped through a 0.8 mm sieve and pre-blended into a 10.0% w/w lactose-monohydrate carrier premix. The downstream indication for this intermediate is post-weaning enteritis in suckling and weaned pigs, where the culturable pathogen burden is dominated by enterotoxigenic Escherichia coli K88/F4 and, in later nursery phases, Clostridium perfringens type C. Compliance for the premix intermediate follows EU Regulation 2019/6 Annex II for non-antibiotic zootechnical additives, where the marketing authorisation holder is required to demonstrate batch-to-batch consistency rather than clinical efficacy as a sole endpoint; the analytical release specification uses VICH GL2 method validation criteria for the HPLC assay of berberine hydrochloride and timosaponin B-II. The API is incorporated at 10.0% w/w in the first dilution bridge, then further diluted to 1.0–3.0 kg per tonne in final complete feed. Each kilogram of finished creep feed is formulated to deliver 25–50 mg of the standardised alkaloid fraction, although published data for this specific formulation configuration are limited and the final dose must be fixed against the target species monograph. Process control on a 500 kg horizontal double-ribbon mixer uses a 1.0 mm screen size, 18 rpm shaft speed, and 12 min dry blending time; 0.5% w/w colloidal silicon dioxide and 2.0% w/w calcium carbonate are added before geometric dilution to displace moisture and control electrostatic adhesion at RH >60%. The blend is packed as a 5 kg or 25 kg premix bag or transferred to a pellet conditioner where the retained pellet temperature is held at 75°C for not more than 45 s. When the conditioner temperature exceeds 82°C, the marker recovery measured by HPLC drops by more than 10% in high-starch matrices, a loss that is not recoverable by post-extrusion coating. Terminal product types include 5 kg and 25 kg powdered premix bags, 1 kg on-farm top-dress packs, and extruded creep feed pellets.

What Limits the Dissolution Rate of Water-Soluble Granules in Oxidised Drinking Water Lines?

Broiler and layer flocks presenting with wet litter and elevated coliform shedding are the primary downstream users of the water-soluble granule presentation, because the oral route maintains intake during acute enteritis when feed consumption drops. The formulation is built around a 40.0% w/w API load wet-granulated with 25.0% w/w dextrose monohydrate, 18.0% w/w lactose monohydrate, 8.0% w/w sodium bicarbonate, 3.0% w/w citric acid anhydrous and 1.5% w/w povidone K30. The compliance package for the granule uses VICH GL49 residual marker criteria and the dissolution test of European Pharmacopoeia 2.9.3; the finished sachet is released only when the percent drug dissolved at 30 min is not less than 80% in phosphate buffer pH 6.8. In drinking water, the final reconstituted concentration is 0.5–2.0 g/L, which requires the premix granule to be fully dispersed within 3 min at 20°C. Oxidised water lines with free chlorine above 0.3 mg/L and iron above 0.2 mg/L have been observed to reduce the apparent concentration of berberine-type alkaloids by 12–18% after 6 h standing time, so the product is not recommended for continuous dosing through heavily scaled galvanised lines. The granulation process itself is more sensitive to shear heat than to moisture. A high-shear wet mass at impeller speed 250 rpm and chopper 1,500 rpm produces localised temperatures above 45°C, causing the dextrose to plasticise and the API to coat the bowl sides; the resulting granules have irregular size distribution and an assay recovery of 88–94%. Fluid-bed top-spray granulation with inlet air 55°C, product temperature 38–42°C, and spray rate 150–250 g/min retains 94–97% of the alkaloid marker and produces a more uniform particle size. The comparative process data are shown below.

After granulation, the material is passed through a 1.0 mm conical mill and dried to a final moisture content of 2.0–3.5% w/w. The packaged product is a 100 g or 500 g sachet for in-line medication, and a 1 kg veterinary dispensing jar for larger farms.

Calf Scour Boluses and Direct Compression Rheology

Neonatal calf rearing units use the API as a 1.0 g dispersible bolus for oral administration during the first 72 h of non-antibiotic enteritis management, where the main targets are enterotoxigenic Escherichia coli F5/K99 and concurrent rotavirus shedding. The direct compression blend contains 30.0% w/w API, 48.5% w/w microcrystalline cellulose PH102, 10.0% w/w crospovidone, 5.0% w/w sucrose ester and 0.5% w/w magnesium stearate. Tablet compliance is evaluated by USP <701> Disintegration, with a limit of not more than 3 min in water at 37°C, and USP <905> Uniformity of Dosage Units for content uniformity. The API is pre-dried at 50°C for 2 h if the ambient relative humidity exceeds 60%, since moisture uptake above 5.0% w/w causes hopper bridging and weight variation above 3.0% RSD on a 16-station tablet press. Compression force is maintained at 25–35 kN using 10.0 mm flat-faced bevel-edge tooling, producing tablets with hardness 60–90 N and friability below 0.8%. Wet granulation is avoided unless the API is pre-stabilised with 2.0% w/w calcium hydrogen phosphate dihydrate; the alkaloid fraction degrades when the wet mass is retained at 40°C for longer than 20 min. Terminal product types include 1.0 g and 2.0 g dispersible boluses, 0.5 g tablets for young calves, and size 7 hard gelatin capsules filled with the same direct compression blend for low-dose administration.

After the extruder discharge temperature exceeds 85°C, the surviving alkaloid content becomes insufficient for field stability in tropical pond conditions, so the feed-mill team moves the herbal API addition to the post-extrusion vacuum coater rather than the pre-conditioning mixer. In warm-water aquaculture, the application is non-antibiotic support against Aeromonas hydrophila enteritis in tilapia and common carp, where the API is first diluted into a 1:100 carrier premix with calcium carbonate and fish oil, then applied at 0.5–2.0 kg per tonne of extruded finished feed. Compliance is based on ISO 22000:2018 feed safety management and the hazard analysis of Codex CAC/RCP 54-2004; the premix is tested for homogeneity using a 10-sample thief probe with acceptance not more than 5.0% RSD. The vacuum coater operates at 55°C jacket temperature, 0.25 MPa vacuum, and 15 min mixing time, depositing the API onto 2.5 mm floating tilapia pellets after extrusion. Coating after extrusion avoids the thermal and shear losses observed in preconditioning where temperatures above 85°C reduce the alkaloid marker recovery by 15–20%. Terminal product types include 20 kg extruded floating tilapia pellets, 25 kg sinking carp pellets, and 1 kg premix top-dress packs for on-farm coating. Controlled pond trial data with this specific configuration are limited; pellet stability and leaching rate under pond immersion should be determined before commercial field deployment.

Hard Gelatin Capsule Filling of a Moisture-Sensitive Herbal API in Canine Damp-Heat Diarrhea Management

A 30,000 capsule/h automatic capsule machine in small-animal veterinary practice fills the API into hard gelatin capsules for adjunctive support in canine chronic large-bowel diarrhea where the traditional veterinary indication is damp-heat accumulation. The capsule fill formulation uses 25.0% w/w API, 45.0% w/w microcrystalline cellulose, 20.0% w/w lactose monohydrate, 8.0% w/w croscarmellose sodium, 1.0% w/w magnesium stearate and 1.0% w/w colloidal silicon dioxide. The capsule process is governed by USP <701> Disintegration and the capsule fill weight acceptance criteria of USP <905> Uniformity of Dosage Units, with additional production controls under FDA 21 CFR Part 211 Subpart F for finished veterinary drug products. The API is preconditioned in a desiccated room at RH 35–40% for 24 h because moisture uptake above 5.0% w/w leads to powder bridging in the dosator and tackiness on the tamping pins. Filling is performed with 5:1 tamping pin compression; the fill weight is controlled to 250 mg ±5.0% for size 1 capsules. Hard gelatin shells are used rather than hypromellose shells in high-humidity climates because the dissolution rate of the herbal extract is less affected by shell cross-linking; however, hard gelatin shells are incompatible with aldehyde-containing excipients and require storage below 25°C to prevent embrittlement. Terminal product types include size 1 hard gelatin capsules, 250 mg and 500 mg, packed in 30-count and 100-count HDPE bottles with desiccant. Published data for this specific formulation configuration are limited, and the product should be released against a stability-indicating HPLC assay for the dual alkaloid markers.